Related Experiment Video
Updated: Jul 14, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory
Jean-Marie Grouin1, Maylis Coste, Pierre Bunouf
1Université de Rouen and AFSSaPS, France. jean-marie@univ-rouen.fr
Statistics in Medicine
|June 15, 2007
Summary
This review examines Bayesian sample size determination (SSD) methods for phase III drug trials. It assesses their regulatory acceptability compared to traditional frequentist approaches.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Drug Development
Background:
- Sample size determination (SSD) is critical for clinical trial success.
- Frequentist methods are the standard for SSD in drug development.
- Bayesian approaches offer alternative strategies for SSD.
Purpose of the Study:
- To review common Bayesian methods for SSD in phase III drug development trials.
- To evaluate the regulatory perspective on SSD in clinical trials.
- To compare Bayesian SSD methods with frequentist approaches for regulatory acceptance.
Main Methods:
- Literature review of Bayesian SSD methodologies.
- Analysis of prior selection in Bayesian trial planning.
- Assessment of Bayesian SSD against regulatory standards.
Main Results:
- Bayesian SSD methods are applicable in non-sequential confirmatory trials.
- The choice of priors significantly impacts Bayesian SSD outcomes.
- Bayesian SSD shows potential to compete with frequentist methods.
Conclusions:
- Bayesian SSD methods warrant consideration for regulatory review.
- Further investigation is needed to establish Bayesian SSD as a regulatory standard.
- Bayesian SSD offers a flexible alternative for optimizing clinical trial sample sizes.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Sample Size Calculation
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...